ImageneBio, Inc. business relationships
Companies named in ImageneBio, Inc.’s 10-K filed 2026-03-10, and public companies whose annual reports name ImageneBio, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.0 / 10
- AI naming
- <1 / 100 Top 73% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in ImageneBio, Inc.’s annual report 2
“On April 29, 2020, Legacy Inmagene entered into a license and collaboration agreement (the "Affibody Agreement") with Affibody AB ("Affibody"), under which Legacy Inmagene received an exclusive license to develop and commercialize any and all products and associated products utilizing ABY-035 in mai...” SEC filing
“On September 28, 2023, Legacy Inmagene entered into an exclusive license and collaboration agreement (the "Celexor Agreement") with Celexor Bio, Inc. ("Celexor").” SEC filing
Companies whose annual reports name ImageneBio, Inc. 2
“ImageneBio will be primarily focused on the development of IMG-007, a monoclonal antibody targeting OX-40 licensed from us.” SEC filing
“We also have an immunology collaboration with ImageneBio and Miragene with respect to drug candidates discovered by us and an in-licensing collaboration with Epizyme (a subsidiary of Ipsen Pharma SAS) with respect to tazemetostat.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.